Ribavirin utilization and clinical effectiveness in children hospitalized with respiratory syncytial virus infection

Journal of Clinical Epidemiology

Volumn 49, Issue 9, 1996, Pages 963-967

  Ohmit, Suzanne E ^a   Moler, Frank W ^b   Monto, Arnold S ^a   Khan, Ali S ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

Author keywords

Antiviral agent; Children; Clinical effectiveness; Hospital duration; Infants; Respiratory syncytial virus; Ribavirin

Indexed keywords

ANTIVIRUS AGENT; RIBAVIRIN;

ARTICLE; ASSISTED VENTILATION; CONGENITAL HEART MALFORMATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG USE; FAILURE TO THRIVE; FEMALE; HOSPITALIZATION; HUMAN; INFANT; LABORATORY DIAGNOSIS; LENGTH OF STAY; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRACTICE GUIDELINE; PRESCHOOL CHILD; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT INFECTION;

EID: 0030248129     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/0895-4356(96)00137-0     Document Type: Article

References (32)

1. 1. Glezen WP, Denny FW. Epidemiology of acute lower respiratory disease in children. N Engl J Med 1973; 288: 498-505.
2. 2. Mufson MA, Levine HD, Wasil RE, Mocega-Gonjalez HE, Krause HE. Epidemiology of respiratory syncytial virus infection among infants and children in Chicago. Am J Epidemiol 1973; 98: 88-95.
3. 3. Meert K, Heideman S, Abella B, Sarnaik AP. Does prematurity alter the course of respiratory syncytial virus infection. Crit Care Med 1990; 18: 1357-1359.
4. 4. Green M, Braver AF, Schenkman KA, Wald ER. Duration of hospitalization in previously well infants with respiratory syncytial virus infection. Pediatr Infect Dis J 1989; 8: 601-605.
5. 5. MacDonald NE, Hall CB, Suffin SC, Alexson C, Harris PJ, Manning JA. Respiratory syncytial virus infection in infants with congenital heart disease. N Engl J Med 1982; 307: 397-400.
6. 6. Groothuis JR, Gutierrez KM, Lauer BA. Respiratory syncytial virus infection in children with bronchopulmonary dysplasia. Pediatrics 1988; 82: 199-203.
7. 7. Ogra PL, Patel J. Respiratory syncytial virus infection and the immuno-compromised host. Pediatr Infect Dis J 1988; 7: 246-249.
8. 8. Meert K, Heidemann S, Lieh-Lai M, Sarnaik AP. Clinical characteristics of respiratory syncytial virus infections in healthy versus previously compromised host. Pediatr Pulmonol 1989; 7: 167-170.
9. 9. Navas L, Wang E, de Carvalho V, Robinson J. Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canada. J Pediatr 1992; 121: 348-354-
10. 10. Moler FW, Khan AS, Meliones JN, Custer JR, Palmisano J, Shope TC. Respiratory syncytial virus morbidity and mortality estimates in congenital heart disease patients: A recent experience. Crit Care Med 1992; 20: 1406-1413.
11. 11. Hall CB, McBride JT, Walsh EE, Bell DM, Gala CL, Hildreth S, Ten Eyck LG, Hall WJ. Aerosolized ribavirin treatment of infants with respiratory syncytial virus infection. N Engl J Med 1983; 308: 1443-1447.
12. 12. Taber LH, Knight V, Gilbert BE, McClung HW, Wilson SZ, Norton HJ, Thurson JM, Gordon WH, Atmar RL, Schlaudt WR. Ribavirin aerosol treatment of bronchiolitis associated with respiratory syncytial virus infection. Pediatrics 1983; 72: 613-618.
13. 13. Hall CB, McBride JT, Gala CL, Hildreth SW, Schnabel KC. Ribavirin treatment of respiratory syncytial virus infection in infants with underlying cardiopulmonary disease. JAMA 1985; 254: 3047-3051.
14. 14. Committee on Infectious Diseases. Use of ribavirin in the treatment of respiratory syncytial virus infection. Pediatrics 1993; 92: 501-504.
15. 15. ICN Pharmaceuticals, Inc. Virazoie (Ribavirin): Prescribing Information. Costa Mesa, California: ICN Pharmaceuticals, Inc.; 1988.
16. 16. Wheeler JG, Wofford J, Turner RB. Historical cohort evaluation of ribavirin efficacy in respiratory syncytial virus infection. Pediatr Infect Dis J 1993; 12: 209-213.
17. 17. Groothuis JR, Woodin KA, Katz R, Robertson AD, McBride JT, Hall CB, McWilliams BC, Lauer BA. Early ribavirin treatment of respiratory syncytial virus infection in high-risk children. J Pediatr 1990; 117: 792-798.
18. 18. Smith DW, Frankel LR, Mathers LH, Tang AT, Ariagno RL, Prober CG. A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection. N Engl J Med 1991; 325: 24-29.
19. 19. Meert KL, Sarnaik AP, Geltnini MJ, Lieh-Lai MW. Aerosolized ribavirin in mechanically ventilated children with respiratory syncytial virus lower respiratory tract disease: A prospective, double-blind, randomized trial. Crit Care Med 1994; 22: 566-572.
20. 20. Begue RE, Dennehy PH. Respiratory syncytial virus infections at Rhode Island Hospital: Use of ribavirin. RI Med J 1991; 74: 17-22.
21. 21. Stretton M, Ajizian SJ, Mitchell I, Newth CJ. Intensive care course and outcome of patients infected with respiratory syncytial virus. Pediatr Pulmonol 1992; 13: 143-150.
22. 22. Wald ER, Dashefsky B, Green M. In re ribavirin: A case of premature adjudication? J Pediatr 1988; 112: 154-158.
23. 23. Ray CG. Ribavirin: Ambivalence about an antiviral agent. Am J Dis Child 1988; 142: 488-489.
24. 24. SAS Institute, Inc. SAS Statistical Software, release 6.0, Gary, North Carolina: SAS Institute, Inc.; 1988.
25. 25. Statistics and Epidemiology Research Corporation. EGRET Statistical Software. Seattle, Washington, SERC, Inc.; 1988.
26. 26. PCGROUP Statistical Software. Austin, Texas: 1993.
27. 27. Moler FW, Bandy KP, Custer JR. Ribavirin for severe RSV infection. N Engl J Med 1991; 325: 1884-1885. [letter]
28. 28. Wald ER, Dashefsky B. Ribavirin: Red Book committee recommendations questions. Pediatrics 1994: 93: 672-673.
29. 29. Krafte-Jacobs B, Holbrook PR. Ribavirin in severe respiratory syncytial virus infection. Crit Care Med 1994: 22; 541-543.
30. 30. Ribavirin. In: AHFS Drug Information 91. Bethesda, Maryland: American Society of Hospital Pharmacists, Inc.; 1991: 372-379.
31. 31. Martin JT, Kugler JD, Gumbiner CH, Brown JC, Murphy KR, Colombo JL, McManus BM. Refractory congestive heart failure after ribavirin in infants with heart disease and respiratory syncytial virus. Nebr Med J 1990; 75: 23-26.
32. 32. Decker JA, Shults RA. Ribavirin: Hazard evaluation and technical assistance interim report HETA 91-104-Natl Inst Occup Safety Health 1992; January, pp. 1-33.